Name: Clindamycin
Brand: Selleck Chemicals
SKU: S2830
Availability: InStock
Rating: 5 (3 reviews)

Jump to

Quality Control

Batch: Purity: 98.55%

98.55

Related Targets	Integrase Antibiotics Anti-infection Fungal Antiviral COVID-19 Parasite Reverse Transcriptase HIV HCV Protease
Other Bacterial Inhibitors	BTZ043 Racemate Teicoplanin Pefloxacin Mesylate Ceftiofur Solithromycin 6-Methoxydihydrosanguinarine Proanthocyanidins Flagelin 22 Taurolidine Skatole

Solubility

In vitro
Batch:

DMSO : 85 mg/mL (200.0 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 85 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.000mg/ml (2.35mM)	Taking the 1 mL working solution as an example, add 50 μL of 20 mg/ml clarified DMSO stock solution to 400 μL of PEG300, mix evenly to clarify it; add 50 μL of Tween80 to the above system, mix evenly to clarify; then continue to add 500 μL of ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

%

% Tween 80

% ddH₂O

% DMSO

+

%

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	424.98	Formula	C₁₈H₃₃ClN₂O₅S	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	18323-44-9	--		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent
Synonyms	N/A			SMILES	CCCC1CC(N(C1)C)C(=O)NC(C2C(C(C(C(O2)SC)O)O)O)C(C)Cl

Read more about storage stability stock solution CAS number SMILES

Mechanism of Action

In vitro	Clindamycin is a semisynthetic analogue of lincomycin. It primarily inhibits the initiation of peptide chain synthesis by deregulating enzyme-catalyzed initiation of peptide bounds. This compound appears to have a modest effect on protein synthesis by certain mammalian cells. It is active against most gram-positive aerobic bacteria. This antibiotic is about eight times more active than lincomycin against Staphylococcus aureus and Streptococcus pneumonia. It is four times more active than erythromycin against S. aureus and is active even against strains that are resistant to erythromycin, penicillin, and methicillin. It is active against gram-positive anaerobes. This agent highly activates against Bacteroides specie. It also alters the bacterial surface in such a way that phagocytosis and intracellular killing of the bacteria is greatly facilitated. This drug potentiates opsonization and phagocytosis.
In vivo	Clindamycin (50mg/kg daily administrated by intramuscular) increases the survival rate of monkeys infected with penicillin-resistant S. aureu to 87.5% (7/8). This compound (40 mg/kg administrated three times daily) protects 87.5% (7/8) of rabbits from anaerobic pulmonary infections induced by transtracheal inoculation of a mixture of B. fragillis, Streptococcus morbillorm, Fusobacterium nucleatum and Eubacterium lentum. This chemical (400 mg/kg treated by mixed in the diet) increases survival rate of mice infected with the Toxoplasma gondii to 100%, while all animals die in untreated group.
References	[1] https://pubmed.ncbi.nlm.nih.gov/1262717/ [2] https://pubmed.ncbi.nlm.nih.gov/6818656/ [3] https://pubmed.ncbi.nlm.nih.gov/4994902/ [4] https://pubmed.ncbi.nlm.nih.gov/7014632/ [5] https://pubmed.ncbi.nlm.nih.gov/4386950/ [6] https://pubmed.ncbi.nlm.nih.gov/7075325/ [7] https://pubmed.ncbi.nlm.nih.gov/4684885/

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-01-21)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT07357103	NOT_YET_RECRUITING	Pneumocystis; Pneumocystis Infection; Pneumocystis Carinii Infection; Pneumocystis Carinii; Infection, Resulting From HIV Disease; Pneumocystis Jirovecii Pneumonia; Pneumocystis Jirovecii Infection; Pneumocystosis Associated With AIDS; Pneumocystosis; Pneumonia (Etiology)	McGill University Health Centre/Research Institute of the McGill University Health Centre	2026-03	PHASE4
NCT07357103	NOT_YET_RECRUITING	Pneumocystis; Pneumocystis Infection; Pneumocystis Carinii Infection; Pneumocystis Carinii; Infection, Resulting From HIV Disease; Pneumocystis Jirovecii Pneumonia; Pneumocystis Jirovecii Infection; Pneumocystosis Associated With AIDS; Pneumocystosis; Pneumonia (Etiology)	McGill University Health Centre/Research Institute of the McGill University Health Centre	2026-03	PHASE4
NCT05137119	RECRUITING	Staphylococcus Aureus Bacteremia	University of Melbourne	2022-02-16	PHASE4
NCT05137119	RECRUITING	Staphylococcus Aureus Bacteremia	University of Melbourne	2022-02-16	PHASE4
NCT06494072	RECRUITING	Community Acquired Pneumonia in Children	Medical College of Wisconsin	2024-08-22	PHASE4
NCT06494072	RECRUITING	Community Acquired Pneumonia in Children	Medical College of Wisconsin	2024-08-22	PHASE4

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Clindamycin Bacterial inhibitor

Chemical Structure

Molecular Weight: 424.98